Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):655-656. doi: 10.1007/s00259-020-04983-9.

Matthew J Roberts^{1

2

3

4}, Andrew Morton⁵, Peter Donato^{6

5}, Samuel Kyle^{5

7}, David A Pattison^{5

7}, Paul Thomas^{5

7}, Geoff Coughlin⁶, Rachel Esler⁶, Nigel Dunglison⁶, Robert A Gardiner^{6

8

9

10}, Suhail A Doi¹¹, Louise Emmett^{12

13}, John Yaxley^{6

5}

¹ Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia. [email protected].
² Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Australia. [email protected].
³ Department of Urology, Redcliffe Hospital, Brisbane, Australia. [email protected].
⁴ Faculty of Medicine, The University of Queensland, Brisbane, 4006, Australia. [email protected].
⁵ Faculty of Medicine, The University of Queensland, Brisbane, 4006, Australia.
⁶ Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
⁷ Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
⁸ Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, Australia.
⁹ Griffith University, Brisbane, Queensland, Australia.
¹⁰ Edith Cowan University, Joondalup, Western Australia.
¹¹ Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
¹² Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
¹³ Faculty of Medicine, University of New South Wales, Sydney, Australia.

No abstract available

Publication types